Posted by Michael Wonder on 25 Nov 2020
Liquidia receives complete response letter from FDA for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension
25 November 2020 - Complete response letter does not cite need for additional clinical studies.
Liquidia Technologies today announced that the US FDA has issued a complete response letter for the company’s new drug application for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension.
